- Home
- AKTX vs OPTH Comparison
AKTX vs OPTH Comparison
Compare AKTX & OPTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AKTX | OPTH |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.2M | 15.5M |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | AKTX | OPTH |
|---|---|---|
| Price | $13.51 | $4.61 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $33.50 | N/A |
| AVG Volume (30 Days) | 92.9K | ★ 99.4K |
| Earning Date | 05-14-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.12 | $4.00 |
| 52 Week High | $29.32 | $5.45 |
Technical Indicators
Market Signals| Indicator | AKTX | OPTH |
|---|---|---|
| Relative Strength Index (RSI) | 56.69 | 61.62 |
| Support Level | $0.32 | $4.47 |
| Resistance Level | $29.32 | $5.45 |
| Average True Range (ATR) | 1.86 | 0.42 |
| MACD | 0.20 | 0.01 |
| Stochastic Oscillator | 74.44 | 40.69 |
Price Performance
Historical ComparisonAbout AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) built around novel, proprietary payloads utilizing powerful biology to attack cancer. Its payload, PH1, targets RNA splicing by modulating the spliceosome, a complex machinery in the cell that converts pre-RNA into spliced RNA for translation into vital proteins for cell survival and growth. Its product pipeline is AKTX-101, which targets the Trop2 receptor on cancer cells and, with a proprietary linker, enables it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. and AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen expressed across multiple solid tumors.